Abstract To assess the relationship between insulin-like growth factor II (IGF2) and H19 gene expression at the cellular level, we have examined the distribution of IGF2 and H19 mRNA by means of in situ hybridization in hepatic malignancies consisting of hepatocellular carcinoma (HCC), cholangiocellular carcinoma (CCC), and metastatic liver cancer (MLC). In HCC, 15 of 27 tumors (56%) and 11 of 27 tumors (41%) demonstrated increased IGF2 and H19 gene expression, respectively. Of 16 HCCs with increased expression of either IGF2 or H19, 10 tumors coexpressed both transcripts at comparable levels. Moreover, the spatiotemporal distribution and the cellular localization of the two gene transcripts were almost identical, suggesting the presence of a reciprocal relation between IGF2 and H19. In addition, 5 HCCs showed increased IGF2 expression without concomitant H19 expression, whereas 1 HCC showed increased H19 expression without IGF2 transcripts. However, 11 HCCs showed no IGF2 or H19 expression. On the other hand, neither IGF2 transcripts nor H19 transcripts were detected in 2 CCCs or 10 MLCs studied. The data suggest that IGF2 and/or H19 gene expression may be characteristic of some HCCs.
Introduction
Insulin-like growth factor II (IGF2), whose gene is located on chromosome 11p15.5, is a growth factor believed to be important in fetal growth and development (Moses et al. 1980; Brown et al. 1986; Humbel 1990 ). The human IGF2 gene is one of a dozen genes which are subject to genomic imprinting, with the paternal allele expressed and the maternal allele silent. The IGF2 gene is a complex transcriptional unit that contains four different promoters (P1-P4) van Dijk et al. 1991) . During fetal life, a high level of IGF2 transcript is expressed mainly from the P2-P4, fetal-type promoters, and the resulting IGF2 serves as a growth factor in several embryonic tissues including fetal liver. In contrast, adult liver demonstrates loss of imprinting (LOI) of IGF2 which is derived from P1, leading to biallelic IGF2 expression, while IGF2 transcripts derived from P2-P4 show markedly decreased expression, although they remain monoallelically expressed (Vu and Hoffman 1994; Ekström et al. 1995) .
It has been reported that IGF2 plays a role in the pathogenesis of a variety of neoplasms (LeRoith et al. 1995) . Since increased expression of IGF2 in hepatocellular carcinoma (HCC) was originally described by Cariani et al. (1988) , several investigators have reported that IGF2 may play a role in the development of HCC (D'Arville et al. 1991; Lamas et al. 1991; Sohda et al. 1996) .
The H19 gene, which is located 200 kb downstream of IGF2, has also been implicated in tumor development and is believed to function as a tumor suppressor (Zhang and Tycko 1992; Hao et al. 1993 ). H19 has also been shown to be imprinted, with the maternal allele being expressed and the paternal silent, in contrast to IGF2, for which the reverse situation applies. This unique reciprocal relationship, along with the observation that IGF2 and H19 genes are extensively coexpressed during human embryonic/fetal development (Ohlsson et al. 1994) , has lead to the so-called enhancer competition model hypothesis. This model proposes that there exists a regulatory element near the IGF2/ H19 loci that acts as a switch to allow either IGF2 or H19 expression (Pfeifer and Tilghman 1994) .
It was recently reported that the expression of IGF2 and H19 in HCC were related to each other (Takeda et al. 1996; Li et al. 1997) . However, it remains unclear whether high expression of IGF2 and H19 occurs within a single cell. In this study, to assess the relationship between IGF2 and H19 ORIGINAL ARTICLE gene expression at the cellular level in HCC, we carried out in situ hybridization and compared the level and the localization of H19 transcripts. In addition, we examined expression of these transcripts in other liver malignancies: cholangiocellular carcinoma (CCC) and metastatic liver cancer (MLC). The results demonstrated that increased levels of IGF2 expression were detected in approximately half of the HCCs, and the distribution and the intensity of IGF2 transcripts showed a close resemblance to those of H19, whereas other liver cancers showed no detectable levels of IGF2 or H19 gene expression.
Materials and methods

Tissue specimens
The present study comprised 27 HCCs, 2 CCCs, and 10 MLCs, all of which were from an autopsy file of the Fukuoka University Hospital. The diagnosis was based upon histological findings and clinical examination. Routine staining was performed to evaluate histological type. HCC was histologically graded according to the classification of Edmondson and Stainer (1954) , and the results are summarized in Table␣ 1. Of 27 HCCs, 14 were positive for hepatitis C virus antibody (HCVAb) only, 6 were positive for hepatitis B surface antigen (HBsAg) only, 1 was positive for both HBsAg and HCVAb, and 6 were negative for both HBsAg and HCVAb (Table␣ 1).
All liver samples were fixed in buffered 10% formalin and embedded in paraffin. Serial 5-mm-thick sections were cut and mounted on slides coated with 2% 3-aminopropyltriethoxysilane. Slides were then heated at 60°C for 2 h and stored at room temperature until use.
RNA probes
The human IGF2 was a 559-bp fragment corresponding to nucleotides 256-815 obtained from cDNA of phigh2 cloned into pGEM-3. The H19 clone correspond to a EcoRI-SacI fragment of human H19 cDNA cloned into pGEM-7ZF(+). Sense and antisense RNA probes were transcribed from linearized templates using SP6 and T7 RNA polymerases (Promega, Madison, WI, USA), and radiolabeling with [
35 S]-CTP (Amersham, Buckinghamshire, UK).
In situ hybridization
In situ hybridization analyses were performed according to the methods previously described (Wilkins et al. 1989 ). Briefly, hybridization was carried out in a solution containing 50% formamide, 2 ϫ SSC, 0.15␣ M NaCl, 0.2␣ mg/ml Escherichia coli tRNA, 1␣ mg/ml degraded herring sperm DNA, 0.1 mg/ml bovine serum albumin, 10% polyethylene glycol, 0.2 M dithiothreitol, and [ 35 S]-CTP-labeled antisense or sense RNA probe (40,000␣ cpm/ml) at 50°C overnight. After hybridization, the slides were washed in 50% formamide, 2 ϫ SSC at 52°C and in 2 ϫ SSC at room temperature. The slides were then incubated in RNase A solution at 37°C for 30␣ min. For autoradiography, slides were dipped into nuclear emulsion (Amersham) and exposed in light-tight boxes at 4°C for 2 weeks. After development, the slides were counterstained with hematoxylin-eosin.
Results
In situ mRNA hybridization in HCC Among the 27 HCCs examined by in situ hybridization, increased expression of the IGF2 gene was observed in 15 HCC cases (56%), which consisted of 10 of 14 cases associated with hepatitis C virus (HCV), 3 of 6 cases associated with hepatitis B virus (HBV), and 2 of 6 cases negative for both HBV and HCV, and did not include the single case with both HBV and HCV. On the other hand, an increased level of H19 transcripts was detected in 11 (41%) of 27
HCCs. These 11 tumors included 6 of 14 cases positive for HCV, 2 of 6 positive for HBV, and 3 of 6 negative for both HBV and HCV, and also excluded the case with both HBV and HCV. Collectively, 16 of 27 HCCs showed increased expression of either the IGF2 or the H19 gene. Among these 16 HCCs, 10 tumors showed both transcripts, while 5 produced only IGF2 transcripts, and 1 had only H19 transcripts. There appeared to be no obvious, statistically significant correlations among tumors with or without IGF2 and/or H19 expression, in terms of histological and clinical parameters.
With respect to the spatial or cellular localization, IGF2 and H19 transcripts were detected specifically in the cytoplasm of HCC cells. Significant levels of hybridization signal were detected in less-well-differentiated HCC cells which were located in the periphery of HCC tumor nodules, whereas well-differentiated tumor cells in the central area showed no detectable level of transcripts (Fig.␣ 1) . On the other hand, regenerative hepatocytes in cirrhotic liver from nontumorous areas contained low levels of transcripts. All of the 10 tumors with increased IGF2 and H19 transcripts showed almost identical cellular localization of the two transcripts, strongly suggesting that the tumor cells coexpress both transcripts. Furthermore, the levels of the two gene transcripts in these 10 HCCs appeared to be closely and positively correlated (Table␣ 1). Expression of IGF2 and H19 in other liver cancers
Tumors from 10 MLCs were also included in this study. The primary sites are shown in Table␣ 2. Neither IGF2 nor H19 transcripts were expressed in liver metastases or primary tumors, while low levels of both transcripts were detected in the hepatocytes from nonneoplastic lesions. Similarly, in 2 CCCs, neither IGF2 nor H19 transcripts were detected (data not shown).
Discussion
We have examined the expression patterns of the IGF2 and H19 genes in HCC by means of in situ hybridization. It is generally known that the formalin-fixed section technique is also available to perform in situ mRNA hybridization. However, to avoid the degradation of RNA by endogenous RNase, we have used liver sections which were fixed in formalin within 3 h of cardiac arrest. Moreover, we confirmed the specificity by: (1) pretreatment of tissue sections with RNase A (100␣ mg/ml) for 1 h at 37°C before hybridization; (2) hybridization with sense probes; and (3) hybridization of fetal liver samples as positive controls (data not shown). HCC is known to be one of the neoplasms which produce IGF2. Nardone et al. (1996) reported IGF2 expression in HCCs associated with HCV. In addition, Su et al. (1994) reported a role for IGF2 in HCC associated with HBV, i.e., products of the integrated hepatitis B x gene may activate the IGF2 gene. The present study found increased IGF2 expression in 56% of HCCs. The increased expression of IGF2 is envisaged to be advantageous for tumor growth. Most of the growth factors produced by tumor cells are thought to promote the growth of the tumor itself (Heldin and Westermark 1984; Sporn and Roberts 1985) . In the present study, the high level of hybridization signal was detected in less-well-differentiated tumor cells but not in well-differentiated cells, suggesting that IGF2 may act as an autocrine or paracrine growth factor. This notion is supported by our recent observation in that IGF2 protein and Ki-67 antigen, a proliferation marker, are codetected in less-well-differentiated tumor cells (Sohda et al. 1997) . We have also previously demonstrated that in HCC, the increased IGF2 mRNA is transcribed largely from the fetal type promoter, P3, rather that the adult type promoter, P1, and that the level of IGF2 mRNA is comparable to that of IGF2 protein in tumor cells, indicating that IGF2 production is primarily regulated at the gene transcriptional level without significant posttranscriptional modification (Sohda et al. 1996) . These reports by us and others suggest that IGF2 may play a primary role as an autocrine growth factor in HCC.
The H19 gene, located telomeric to IGF2 on chromosome 11p15.5, which is frequently involved in loss of heterozygosity (LOH) in a variety of cancers, including HCC (Viel et al. 1992; Winqvist et al. 1993; Baffa et al. 1996; Besnard-Guérin et al. 1996) , is subject to genomic imprinting with maternal gene expression only. H19 transcripts were detected in 41% of HCCs. Tumors expressing the two transcripts showed similar cellular localization patterns for H19 and IGF2 transcripts, a result consistent with the enhancer competition model. According to the model, the regulatory units telomeric to IGF2 and H19 genes control a switch for either IGF2 or H19 expression, thus leading to reciprocal expression of the two genes (Pfeifer and Tilghman 1994) . This model appears to fit well in endodermal tissues such as liver, or in the endomesodermal mixed tissue including gut, kidney, and lung. In other tissues, such as placenta, skeletal muscle, and brain, the model does not fit, suggesting the involvement of other factors in the control of H19 and IGF2 expression. The model gains support from the observation that biallelic expression of IGF2 appears to be associated with decreased expression of H19 in childhood tumors such as Wilms' tumor and hepatoblastoma, suggesting that H19 plays a role in tumor suppression as a cis-acting repressor of IGF2 Steenman et al. 1994; Moulton et al. 1994) . We have reported that early-stage placentae showed biallelic H19 and monoallelic IGF2 expression in the same placental trophoblasts (Jinno et al. 1995) .
Our present study indicated that neither IGF2 nor H19 transcripts were detected in 11 of 27 HCCs and that comparable levels of the two gene transcripts were seen in 10 tumors (37%). On the other hand, 5 tumors (18.5%) were associated with the upregulation of IGF2 and the downregulation of H19. One tumor (4.5%) was associated with the downregulation of IGF2 and the upregulation of H19. Therefore, our data suggest that, in contrast to Wilms' tumor, in HCC, H19 may have a limited role, and that gene activation of IGF2 and H19 may be involved in the complicated mechanism of hepatocarcinogenesis.
